10-Q

$ABT · Abbott Laboratories

November 4, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Abbott Laboratories filed its quarterly report on Form 10-Q for the period ended September 30, 2026. The document contains the company’s condensed consolidated financial statements for the third quarter and first nine months of fiscal 2026, including balance sheet, income statement, cash flow, and equity information. The excerpt provided is largely machine-readable XBRL tagging rather than narrative text, so detailed dollar figures and management discussion are not visible in this portion.

The filing includes segment-level disclosures for Abbott’s Established Pharmaceutical Products and Nutritional Products businesses. The pharmaceutical segment data is broken out by U.S. and non-U.S. sales, with further detail for key emerging markets and other emerging markets. Nutritional Products is separated into pediatric nutritionals and adult nutritionals, again with U.S. and international breakdowns. These breakdowns are consistent with standard quarterly segment reporting.

Nothing in the provided excerpt indicates a specific unusual event, acquisition, or regulatory action. The filing appears to be a routine quarterly update covering the three- and nine-month periods ended September 30, 2026.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →